Biological function of CD109 in hematopoiesis.
| Project/Area Number |
18K08371
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 54010:Hematology and medical oncology-related
|
|---|
| Research Institution | Kitasato University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | CD109 / 造血分化 / 骨髄造血 / TGFb / TGFbシグナル / トランスフォーミング成長因子 |
|---|
| Outline of Final Research Achievements |
CD109 is a negative regulator for TGFb which is a key regulatory molecule for hematopoiesis and oncogenesis. In the research, we analyzed biological function of CD109 using knockout mice. We found that CD109 was expressed in mature B cells, and in the knockout mice, plasmablasts in the spleen showed tendency of decrease. Of note, expression of CD109 was not observed in the murine bone marrow cells, which was a major difference between human and mice. We also analyzed the value of serum soluble CD109 in healthy volunteers and patients with hematological disorders. The result showed that soluble CD109 had a tendency of increase in patients with immune thrombocytopenia (ITP), and soluble CD109 may be useful for the diagnosis and clinical follow-up for ITP.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究は、造血器腫瘍・骨髄造血の制御因子であるTGFb分子に関わる研究であり、CD109分子についてマウス・ヒトにおける発現が明らかとなった。マウスにおいては骨髄細胞でCD109の発現が認められないことが明確となり、マウスで研究を行う場合には注意が必要であることが判明した。また、ヒト疾患との関連については、血清可溶性CD109の健常人における値が明らかになるとともに、免疫性血小板減少症で可溶性CD109が高値傾向になり、鑑別診断や病態把握に有用である可能性が明らかとなった。
|
Report
(4 results)
Research Products
(26 results)
-
-
-
-
-
-
[Journal Article] Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes.2019
Author(s)
Kawabata H, Usuki K, Shindo-Ueda M, Kanda J, Tohyama K, Matsuda A, Araseki K, Hata T, Suzuki T, Kayano H, Shimbo K, Chiba S, Ishikawa T, Arima N, Nohgawa M, Miyazaki Y, Kurokawa M, Arai S, Mitani K, Takaori-Kondo A; Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes.
-
Journal Title
Int J Hematol.
Volume: 110
Issue: 5
Pages: 533-542
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study2018
Author(s)
Matsuda A, Kawabata H, Tohyama K, Maeda T, Araseki K, Hata T, Suzuki T, Kayano H, Shimbo K, Usuki K, Chiba S, Ishikawa T, Arima N, Nohgawa M, Ohta A, Miyazaki Y, Nakao S, Ozawa K, Arai S, Kurokawa M, Mitani K, Takaori-Kondo A
-
Journal Title
Leukemia Research
Volume: 74
Pages: 137-143
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
